To Determine Whether Myc-driven Transformation In Haematopoietic Cell Lineages Is Dependent On High-levels Of Myc Protein Expression.
Funder
National Health and Medical Research Council
Funding Amount
$371,896.00
Summary
Myc is an essential cellular protein but is also a common drive of cancer in multiple tissues. In blood cancers Myc is frequently overexpressed. In contrast, Myc is rarely overexpressed in early stage solid cancers, although often elevated levels at later stages. We will employ unique models of cancer in which Myc can be activated at different set levels at different times during blood cell development to address what the specific contributions of different levels of Myc are in the evolution of ....Myc is an essential cellular protein but is also a common drive of cancer in multiple tissues. In blood cancers Myc is frequently overexpressed. In contrast, Myc is rarely overexpressed in early stage solid cancers, although often elevated levels at later stages. We will employ unique models of cancer in which Myc can be activated at different set levels at different times during blood cell development to address what the specific contributions of different levels of Myc are in the evolution of blood cancers.Read moreRead less
RNA Polymerase I: A Novel Target In The Treatment Of MYC Driven Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$605,963.00
Summary
Synthesis of ribosomes, the cellular protein synthetic machinery, is dysregulated during cancer leading to the hypothesis that it may be causative in the malignant process. This application will test this hypothesis using novel inhibitors or ribosome biogenesis in a mouse genetic model termed E�-MYC that faithfully that replicates human B-cell lymphoma. These studies will uncover novel mechanisms in malignant transformation and identify new therapeutics in the treatment of human cancer.